35986841_10216840653711318_1105697261150535680_n
Normal view MARC view ISBD view

Formulation and characterization of novel supermagnetic solid lipid nanostructure lipid carrier in situ nasal gel for Zolmitriptan brain targeting // GP // Dr. Dalia Abdel Aty // A.L. Al-Shaimaa Shaaban (2018 - 2019)

By: Ahmed Mohamed Gamal 150907.
Contributor(s): Hossam Mohamed Mahmoud 153147 | Nada Ahmed Abd El-Khalek 150129 | Sohila Khaled Ahmed Mohamed 150673.
Material type: TextTextSeries: Pharmacy distinguished Projects 2019. Publisher: Giza : MSA, 2019Description: 49 p.Subject(s): Nanotechnology | lipid nanostructureDDC classification: 615.1 Online resources: FULL TEXT PRESS HERE Summary: Nanotechnology development started from 20th century. It has the ability to deliver a small molecular weight drugs also the ability to targeting to cells and tissues by macromolecules such as genes, peptides and proteins. A lot of problems are solved by the use of nanotechnology like lipophilic drugs by formulating them as nanoparticles, poorly soluble drugs by decreasing the drug reactions and improving bioavailability. Solid lipid nanoparticles (SLNs) are defined as colloidal particles which is characterized by small particle size, ability to change surface properties and large surface area that facilitates the bioavailability of poorly water soluble molecules also improving the penetration of the drug into the skin and providing the stability. Magnetic nanoparticles (MNPs) are a special type of NPs that is characterized by high magnetic susceptibility which validate it to be used in biomedical application. The particle size should be small and the MNPs must have a high magnetization to facilitate its motion in the blood vessels with an external magnetic field. Zolmitriptan is a selective serotonin receptor agonist which is effective in reducing migrane symptoms. The purpose of the study is to prepare supermagnetic solid lipid nanostructure lipid carrier of Zolmitriptan to enhance its bioavailability and to develop SLNs containing Zolmitriptan. The objectivities are achieving maximum bioavailability, achieving better solubility and achieving controlled sustained release of the drug. In this study, 6 formulas were prepared with different ratios and were evaluated for their particle size with a range of (205.8_ 469.5 d.nm) and zeta potential with a range of (-14.0_ -20 mv) and the entrapment efficiency were (58%_55%).Formula number 4 were the best as it had the slowest release.
List(s) this item appears in: Pharmacy D. G. P 2018 / 2019
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Distinguished Graduation Projects Distinguished Graduation Projects Centeral Library
Soft Copy located on library Cataloge
GP31PH2019 - Ceutics (Browse shelf) Available 82020

Pharmacy - Pharmaceutics

Nanotechnology development started from 20th century. It has the ability to deliver a small
molecular weight drugs also the ability to targeting to cells and tissues by macromolecules such
as genes, peptides and proteins. A lot of problems are solved by the use of nanotechnology like
lipophilic drugs by formulating them as nanoparticles, poorly soluble drugs by decreasing the
drug reactions and improving bioavailability. Solid lipid nanoparticles (SLNs) are defined as
colloidal particles which is characterized by small particle size, ability to change surface
properties and large surface area that facilitates the bioavailability of poorly water soluble
molecules also improving the penetration of the drug into the skin and providing the stability.
Magnetic nanoparticles (MNPs) are a special type of NPs that is characterized by high magnetic
susceptibility which validate it to be used in biomedical application. The particle size should be
small and the MNPs must have a high magnetization to facilitate its motion in the blood vessels
with an external magnetic field. Zolmitriptan is a selective serotonin receptor agonist which is
effective in reducing migrane symptoms. The purpose of the study is to prepare supermagnetic
solid lipid nanostructure lipid carrier of Zolmitriptan to enhance its bioavailability and to develop
SLNs containing Zolmitriptan. The objectivities are achieving maximum bioavailability,
achieving better solubility and achieving controlled sustained release of the drug. In this study, 6
formulas were prepared with different ratios and were evaluated for their particle size with a
range of (205.8_ 469.5 d.nm) and zeta potential with a range of (-14.0_ -20 mv) and the
entrapment efficiency were (58%_55%).Formula number 4 were the best as it had the slowest
release.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer